NCT00268307

Bone Marrow Stem Cell Infusion Following a Heart Attack

Cellular Transplantation of Autologous Bone Marrow-Derived Stem Cells Following Myocardial Infarction

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Minneapolis Heart Institute Foundation · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to determine the safety of giving a patient's own bone marrow-derived stem cells delivered with a catheter (tube) into the coronary arteries (blood vessels of the heart). Stem cells are simple cells produced by the bone marrow that can develop into many types of cells. It is possible that these cells will decrease the size of damage caused to the heart from a heart attack and increase the pumping efficiency of the heart; which can be decreased due to a heart attack. The stem cells will be taken from bone marrow and then given back into the heart vessels.

Detailed description

This protocol will test the hypothesis that an intracoronary infusion of autologous, unfractionated, bone marrow mononuclear cells will attenuate infarct size and improve left-ventricular function in 60 patients following an acute anterior myocardial infarction who have undergone successful revascularization with PTCA/stenting.

Conditions

• Acute Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Autologous, Unfractionated Bone Marrow Mononuclear Cells	Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.

Timeline

• Start date: 2005-12-01
• Primary completion: 2010-01-01
• Completion: 2010-09-01
• First posted: 2005-12-22
• Last updated: 2013-12-05

Locations

1 site across 1 country: United States